


Downstream Process Intensification for Challenging Large Modalities in Cell & Gene Therapy Bioprocessing

 28th August 2024

 3:00 PM - 4:00 PM (日本時間)

REGISTER NOW

FLOW OF PROGRAMME

Time	Programme Agenda
3PM-3:45PM	<p>Speaker Session</p> <ul style="list-style-type: none"> • Amplifying downstream processing efficiency of nucleic acid targets and large viral vectors with next-generation nanofiber technology • Developing strategies to address the rapidly expanding pipeline of complex and diverse modalities • Achieving intensified productivity through an integrated approach that combines disruptive technologies with existing single-use infrastructures <p>Marc Hummersone, <i>Senior Director, Research & Development, Astrea Bioseparations</i></p>
3:45PM-4:00PM	Live Q&A

Speaker

Marc Hummersone brings over 20 years of project and managerial experience across major technology companies, including AstraZeneca, General Electric Healthcare, and Cytiva. He has developed novel chromatographic media and contributed to drug discovery, notably in the development of Fibro chromatography products and the BRCA-mutated ovarian cancer drug, Lynparza. Marc has held positions such as Company Director, Chief Scientific Officer, and Department Director, and holds a PhD in Chemistry from University College, London



Marc Hummersone

Senior Director, Research & Development,
Astrea Bioseparations

REGISTER NOW